165 related articles for article (PubMed ID: 14576153)
1. Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody.
Lu D; Zhang H; Ludwig D; Persaud A; Jimenez X; Burtrum D; Balderes P; Liu M; Bohlen P; Witte L; Zhu Z
J Biol Chem; 2004 Jan; 279(4):2856-65. PubMed ID: 14576153
[TBL] [Abstract][Full Text] [Related]
2. A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity.
Dong J; Sereno A; Aivazian D; Langley E; Miller BR; Snyder WB; Chan E; Cantele M; Morena R; Joseph IB; Boccia A; Virata C; Gamez J; Yco G; Favis M; Wu X; Graff CP; Wang Q; Rohde E; Rennard R; Berquist L; Huang F; Zhang Y; Gao SX; Ho SN; Demarest SJ; Reff ME; Hariharan K; Glaser SM
MAbs; 2011; 3(3):273-88. PubMed ID: 21393993
[TBL] [Abstract][Full Text] [Related]
3. A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity.
Lu D; Zhang H; Koo H; Tonra J; Balderes P; Prewett M; Corcoran E; Mangalampalli V; Bassi R; Anselma D; Patel D; Kang X; Ludwig DL; Hicklin DJ; Bohlen P; Witte L; Zhu Z
J Biol Chem; 2005 May; 280(20):19665-72. PubMed ID: 15757893
[TBL] [Abstract][Full Text] [Related]
4. A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.
Schanzer JM; Wartha K; Croasdale R; Moser S; Künkele KP; Ries C; Scheuer W; Duerr H; Pompiati S; Pollman J; Stracke J; Lau W; Ries S; Brinkmann U; Klein C; Umana P
J Biol Chem; 2014 Jul; 289(27):18693-706. PubMed ID: 24841203
[TBL] [Abstract][Full Text] [Related]
5. Single variable domain antibody as a versatile building block for the construction of IgG-like bispecific antibodies.
Shen J; Vil MD; Jimenez X; Zhang H; Iacolina M; Mangalampalli V; Balderes P; Ludwig DL; Zhu Z
J Immunol Methods; 2007 Jan; 318(1-2):65-74. PubMed ID: 17126853
[TBL] [Abstract][Full Text] [Related]
6. Single variable domain-IgG fusion. A novel recombinant approach to Fc domain-containing bispecific antibodies.
Shen J; Vil MD; Jimenez X; Iacolina M; Zhang H; Zhu Z
J Biol Chem; 2006 Apr; 281(16):10706-14. PubMed ID: 16481314
[TBL] [Abstract][Full Text] [Related]
7. Impact of Cell-surface Antigen Expression on Target Engagement and Function of an Epidermal Growth Factor Receptor × c-MET Bispecific Antibody.
Jarantow SW; Bushey BS; Pardinas JR; Boakye K; Lacy ER; Sanders R; Sepulveda MA; Moores SL; Chiu ML
J Biol Chem; 2015 Oct; 290(41):24689-704. PubMed ID: 26260789
[TBL] [Abstract][Full Text] [Related]
8. A bi-functional antibody-receptor domain fusion protein simultaneously targeting IGF-IR and VEGF for degradation.
Shen Y; Zeng L; Novosyadlyy R; Forest A; Zhu A; Korytko A; Zhang H; Eastman SW; Topper M; Hindi S; Covino N; Persaud K; Kang Y; Burtrum D; Surguladze D; Prewett M; Chintharlapalli S; Wroblewski VJ; Shen J; Balderes P; Zhu Z; Snavely M; Ludwig DL
MAbs; 2015; 7(5):931-45. PubMed ID: 26073904
[TBL] [Abstract][Full Text] [Related]
9. The effect of variable domain orientation and arrangement on the antigen-binding activity of a recombinant human bispecific diabody.
Lu D; Jimenez X; Witte L; Zhu Z
Biochem Biophys Res Commun; 2004 May; 318(2):507-13. PubMed ID: 15120630
[TBL] [Abstract][Full Text] [Related]
10. XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer.
Schanzer JM; Wartha K; Moessner E; Hosse RJ; Moser S; Croasdale R; Trochanowska H; Shao C; Wang P; Shi L; Weinzierl T; Rieder N; Bacac M; Ries CH; Kettenberger H; Schlothauer T; Friess T; Umana P; Klein C
MAbs; 2016; 8(4):811-27. PubMed ID: 26984378
[TBL] [Abstract][Full Text] [Related]
11. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
[TBL] [Abstract][Full Text] [Related]
12. Functional Domain Order of an Anti-EGFR × Anti-CD16 Bispecific Diabody Involving NK Cell Activation.
Kuwahara A; Nagai K; Nakanishi T; Kumagai I; Asano R
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255436
[TBL] [Abstract][Full Text] [Related]
13. A bispecific transmembrane antibody simultaneously targeting intra- and extracellular epitopes of the epidermal growth factor receptor inhibits receptor activation and tumor cell growth.
Müller N; Hartmann C; Genssler S; Koch J; Kinner A; Grez M; Wels WS
Int J Cancer; 2014 Jun; 134(11):2547-59. PubMed ID: 24243620
[TBL] [Abstract][Full Text] [Related]
14. Cross-arm binding efficiency of an EGFR x c-Met bispecific antibody.
Zheng S; Moores S; Jarantow S; Pardinas J; Chiu M; Zhou H; Wang W
MAbs; 2016; 8(3):551-61. PubMed ID: 26761634
[TBL] [Abstract][Full Text] [Related]
15. Balancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) × c-MET Antibodies and Antibody-Drug Conjugates.
Sellmann C; Doerner A; Knuehl C; Rasche N; Sood V; Krah S; Rhiel L; Messemer A; Wesolowski J; Schuette M; Becker S; Toleikis L; Kolmar H; Hock B
J Biol Chem; 2016 Nov; 291(48):25106-25119. PubMed ID: 27694443
[TBL] [Abstract][Full Text] [Related]
16. Nanocell targeting using engineered bispecific antibodies.
Taylor K; Howard CB; Jones ML; Sedliarou I; MacDiarmid J; Brahmbhatt H; Munro TP; Mahler SM
MAbs; 2015; 7(1):53-65. PubMed ID: 25523746
[TBL] [Abstract][Full Text] [Related]
17. Bispecific antibody CD73xEGFR more selectively inhibits the CD73/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFR.
Ploeg EM; Samplonius DF; Xiong X; Ke X; Hendriks MAJM; Britsch I; van Wijngaarden AP; Zhang H; Helfrich W
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37734877
[TBL] [Abstract][Full Text] [Related]
18. A human IgG-like bispecific antibody co-targeting epidermal growth factor receptor and the vascular endothelial growth factor receptor 2 for enhanced antitumor activity.
Chen Z; Xie W; Acheampong DO; Xu M; He H; Yang M; Li C; Luo C; Wang M; Zhang J
Cancer Biol Ther; 2016; 17(2):139-50. PubMed ID: 26671532
[TBL] [Abstract][Full Text] [Related]
19. Humanization of the bispecific epidermal growth factor receptor x CD3 diabody and its efficacy as a potential clinical reagent.
Asano R; Sone Y; Makabe K; Tsumoto K; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
Clin Cancer Res; 2006 Jul; 12(13):4036-42. PubMed ID: 16818703
[TBL] [Abstract][Full Text] [Related]
20. Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis.
McCall AM; Adams GP; Amoroso AR; Nielsen UB; Zhang L; Horak E; Simmons H; Schier R; Marks JD; Weiner LM
Mol Immunol; 1999 May; 36(7):433-45. PubMed ID: 10449096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
